Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Brain Neoplasms 3Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 29Bevacizumab 14Radiotherapy 12Trastuzumab 10Lomustine 9Capecitabine 8paclitaxel-Angiopep-2 conjugate 6Nivolumab 6pembrolizumab 5dabrafenib 5abemaciclib 5Radiation 5icotinib 4Surgical Procedures, Operative 4Paclitaxel 4Lapatinib 4Irinotecan 4Flucytosine 4Dianhydrogalactitol 4Corticotropin-Releasing Hormone 4Chlorotoxin 4Carboplatin 4vocimagene amiretrorepvec 3verubulin 3tucatinib 3osimertinib 3motexafin gadolinium 3XL647 3Spermine Synthase 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Brain Neoplasms × 5-fluoropentyl-2-methylmalonic acid × Clear all
NCT00696943 2013-02-15

18F ML-10 for Early Detection of Response of Brain Metastases to SRS

Aposense Ltd.

Phase 2 Terminated
1 enrolled
CNS

Brain Neoplasms

NCT00791063 2013-02-13

18F ML-10 for Early Detection of Response of Brain Metastases to WBRT

Aposense Ltd.

Phase 2 Completed
10 enrolled
CNS

Brain Neoplasms

NCT00805636 2010-05-12

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Aposense Ltd.

Phase 2 Unknown
30 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡